Suppression of Host p53 Is Critical for Plasmodium Liver-Stage Infection

Cell Reports

Volumn 3, Issue 3, 2013, Pages 630-637

  Kaushansky, Alexis ^a   Ye, Albert S ^b,c   Austin, Laura S ^a,d   Mikolajczak, Sebastian A ^a   Vaughan, Ashley M ^a   Camargo, Nelly ^a   Metzger, Peter G ^a   Douglass, Alyse N ^a   MacBeath, Gavin ^c   Kappe, Stefan H I ^a,d  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NUTLIN 3; PROTEIN BAD; PROTEIN BCL 2; PROTEIN HYDROLYSATE; PROTEIN KINASE B BETA; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIVER CELL; MALARIA; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PARASITE LOAD; PARASITE SURVIVAL; PLASMODIUM YOELII; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ANIMALS; AUTOPHAGY; CELL PROLIFERATION; CELL SURVIVAL; HEPATOCYTES; HOST-PARASITE INTERACTIONS; IMIDAZOLES; LIFE CYCLE STAGES; LIVER; MICE; MICE, TRANSGENIC; MUTATION; PIPERAZINES; PLASMODIUM YOELII; PROTEIN ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

MUS; PLASMODIUM PARASITES; PLASMODIUM YOELII; RODENTIA;

EID: 84875804444     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.02.010     Document Type: Article

References (24)

1. Albuquerque S.S., Carret C., Grosso A.R., Tarun A.S., Peng X., Kappe S.H., Prudêncio M., Mota M.M. Host cell transcriptional profiling during malaria liver stage infection reveals a coordinated and sequential set of biological events. BMC Genomics 2009, 10:270.
2. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9:862-873.
3. Carrolo M., Giordano S., Cabrita-Santos L., Corso S., Vigário A.M., Silva S., Leirião P., Carapau D., Armas-Portela R., Comoglio P.M., et al. Hepatocyte growth factor and its receptor are required for malaria infection. Nat. Med. 2003, 9:1363-1369.
4. Eferl R., Ricci R., Kenner L., Zenz R., David J.P., Rath M., Wagner E.F. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003, 112:181-192.
5. Fidock D.A. Drug discovery: priming the antimalarial pipeline. Nature 2010, 465:297-298.
6. García-Cao I., García-Cao M., Martín-Caballero J., Criado L.M., Klatt P., Flores J.M., Weill J.C., Blasco M.A., Serrano M. " Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 2002, 21:6225-6235.
7. Haller D., Mackiewicz M., Gerber S., Beyer D., Kullmann B., Schneider I., Ahmed J.S., Seitzer U. Cytoplasmic sequestration of p53 promotes survival in leukocytes transformed by Theileria. Oncogene 2010, 29:3079-3086.
8. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4:1-7.
9. Kaushansky A., Kappe S.H. The crucial role of hepatocyte growth factor receptor during liver-stage infection is not conserved among Plasmodium species. Nat. Med. 2011, 17:1180-1181.
10. Leirião P., Albuquerque S.S., Corso S., van Gemert G.J., Sauerwein R.W., Rodriguez A., Giordano S., Mota M.M. HGF/MET signalling protects Plasmodium-infected host cells from apoptosis. Cell. Microbiol. 2005, 7:603-609.
11. Li T., Kon N., Jiang L., Tan M., Ludwig T., Zhao Y., Baer R., Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149:1269-1283.
12. Luckert K., Gujral T.S., Chan M., Sevecka M., Joos T.O., Sorger P.K., Macbeath G., Pötz O. A dual array-based approach to assess the abundance and posttranslational modification state of signaling proteins. Sci. Signal. 2012, 5:pl1.
13. Mackinnon M.J., Marsh K. The selection landscape of malaria parasites. Science 2010, 328:866-871.
14. Secchiero P., Bosco R., Celeghini C., Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr. Pharm. Des. 2011, 17:569-577.
15. Sevecka M., Wolf-Yadlin A., MacBeath G. Lysate microarrays enable high-throughput, quantitative investigations of cellular signaling. Mol. Cell. Proteomics 2011, 10. M110.005363.
16. Silvie O., Rubinstein E., Franetich J.F., Prenant M., Belnoue E., Rénia L., Hannoun L., Eling W., Levy S., Boucheix C., Mazier D. Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat. Med. 2003, 9:93-96.
17. Snow R.W., Guerra C.A., Noor A.M., Myint H.Y., Hay S.I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005, 434:214-217.
18. Sturm A., Amino R., van de Sand C., Regen T., Retzlaff S., Rennenberg A., Krueger A., Pollok J.M., Menard R., Heussler V.T. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 2006, 313:1287-1290.
19. Tarun A.S., Baer K., Dumpit R.F., Gray S., Lejarcegui N., Frevert U., Kappe S.H. Quantitative isolation and in vivo imaging of malaria parasite liver stages. Int. J. Parasitol. 2006, 36:1283-1293.
20. Tarun A.S., Peng X., Dumpit R.F., Ogata Y., Silva-Rivera H., Camargo N., Daly T.M., Bergman L.W., Kappe S.H. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc. Natl. Acad. Sci. USA 2008, 105:305-310.
21. van de Sand C., Horstmann S., Schmidt A., Sturm A., Bolte S., Krueger A., Lütgehetmann M., Pollok J.M., Libert C., Heussler V.T. The liver stage of Plasmodium berghei inhibits host cell apoptosis. Mol. Microbiol. 2005, 58:731-742.
22. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
23. Vaughan A.M., Aly A.S., Kappe S.H. Malaria parasite pre-erythrocytic stage infection: gliding and hiding. Cell Host Microbe 2008, 4:209-218.
24. Wang J., Zheng T., Chen X., Song X., Meng X., Bhatta N., Pan S., Jiang H., Liu L. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro. J. Gastroenterol. Hepatol. 2011, 26:371-377.